Vuja De is exploiting a unique, targetable vulnerability of cancer. This vulnerability stems from the dependence of undetected, microscopic, disseminated tumor cells and micrometastatic tumors on a unique phenotype that includes stress adaptation, survival & dormancy, which we have coined “Metastatic Endurance” (ME). ME enables these microscopic tumors to persist undetected at secondary sites and eventually start to rapidly divide and form overt deadly tumors. We find and develop drugs that disable ME.
This is a game-changing approach to addressing metastatic cancer recurrence, the cause of ~90% of cancer deaths.